pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
309
stories
4d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
5d
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
5d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
5d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
7d
STAT+: Up and down the ladder: The latest comings and goings
stat
7d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
7d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
7d
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
7d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
7d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
7d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
8d
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
stat
8d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
8d
STAT+: European regulators take steps to bolster clinical trial transparency
stat
8d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
8d
FDA panel confronting peptide controversy
stat
8d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
8d
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
fiercebiotech
8d
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
biospace
8d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
8d
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
8d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
8d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
9d
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
endpoints
9d
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
9d
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
9d
Make or break: Commercial hires critical for success
biospace
9d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
9d
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
9d
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
endpoints
← prev
page 2 of 11
next →
